WolverHeme Happy Hour

In this episode, Anthony and Bernie discuss the important role of community hematology. We discuss innovative research models, partnerships between community and academic practices, and ways to improve care for hematology patients who live near and far!

In this episode, Bernie and Anthony review the optimal management of febrile neutropenia! We talk about some historical data, optimal patient workup, proper selection of antibiotics, and a discussion of newer data regarding early antibiotic de-escalation in FN.

We're back after a summer break! In this episode, Anthony and Bernie review the optimal approach to antimicrobial prophylaxis in hematology patients. How do you best choose prophylaxis for your patients? Where are we using data and where are we just making things up? Does everyone need antifungal, antibacterial, antiviral, and anti-PJP prophylaxis? We will demystify prophylaxis guidelines for you!

In this episode, Bernie and Anthony talk about some BIG changes in cytarabine dosing in AML consolidation after a recent practice changing article. Will this change your practice? Hunault, et al. NEJM. 2025.https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400326

In this episode, Bernie and Anthony are joined by the Myeloma Man Dr. Manni Mohyuddin and lymphoma expert Dr. David Russler-Germain to discuss the very recent ODAC decisions on the STARGLO (glofitamab + GemOx) and AQUILA (daratumumab for smoldering multiple myeloma) trials. Did ODAC do their due diligence, or are there double standards? There is a lot to unpack in this episode!

This is a special encore video presentation of Anthony and Bernie teaming up with the Common Sense Oncology Journal Club series to discuss the SWOG1826 and STARGLO clinical trials. Tycel Phillips, MD, and Manju Sengar, MD join Anthony and Bernie for a great discussion of the trials and how they should impact practice! Join the Common Sense Oncology movement here! https://commonsenseoncology.org/

Joining the discussion are Victoria Nachar, an outpatient hematology pharmacist from the University of Michigan with expertise in lymphoma and myeloma, and James Davis, a malignant hematology pharmacist and assistant professor at MUSC, known for his deep knowledge in multiple myeloma. They explore the management of cytokine release syndrome (CRS) in patients receiving bispecific antibodies, comparing it to CAR-T therapies. They discuss current treatment strategies, the role of prophylactic tocilizumab, and the importance of tailored approaches in patient care.

Join Dr. Anand Patel, a hematology MD and leading educator, alongside Dr. Charlie Foucar, a brilliant hematologist, as they delve into the controversial journey of gemtuzumab in treating acute myeloid leukemia (AML). They discuss its dramatic rise and fall, backed by intriguing studies and data interpretations. Hear them analyze treatment outcomes and dosing strategies while unpacking biases in clinical research. Their engaging banter, peppered with humor and personal anecdotes, makes complex medical discussions entertaining and enlightening!

Join Julia Brown, PharmD, a pediatric hematology/oncology pharmacist, and Lydia Benitez, an adult leukemia pharmacist, as they dive into the evolving landscape of blinatumomab in acute lymphoblastic leukemia (ALL). They discuss the impactful findings of the AALL1731 trial and ECOG-1910, shedding light on improved survival rates. The conversation touches on practical challenges like home infusion, patient monitoring strategies, and the exciting potential of subcutaneous formulations, all while emphasizing equitable access for vulnerable populations.

AQUILA is a constellation shaped like an eagle, and also a hotly debated myeloma trial of daratumumab in smoldering multiple myeloma. In this episode, Bernie and Anthony are joined by myeloma expert Manni Mohyuddin to discuss the study's findings and whether or not they should change practice! Grab a drink and listen in for an exciting discussion. Note: L'aquila is Italian for eagle! AQUILA: Dimopoulos MA, et al. N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029. Epub ahead of print. PMID: 39652675.